188 related articles for article (PubMed ID: 38272046)
1. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
[TBL] [Abstract][Full Text] [Related]
2. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial.
Welzel T; Atkinson A; Schöbi N; Andre MC; Bailey DGN; Blanchard-Rohner G; Buettcher M; Grazioli S; Koehler H; Perez MH; Trück J; Vanoni F; Zimmermann P; Sanchez C; Bielicki JA; Schlapbach LJ;
Lancet Child Adolesc Health; 2023 Apr; 7(4):238-248. PubMed ID: 36746174
[TBL] [Abstract][Full Text] [Related]
3. Swissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) involving 10 secondary and tertiary paediatric hospitals in Switzerland.
Schöbi N; Sanchez C; Welzel T; Bamford A; Webb K; Rojo P; Tremoulet A; Atkinson A; Schlapbach LJ; Bielicki JA;
BMJ Open; 2024 Apr; 14(4):e078137. PubMed ID: 38670610
[TBL] [Abstract][Full Text] [Related]
4. Cardiac assessment and inflammatory markers in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV2 (PIMS-TS) treated with methylprednisolone versus intravenous immunoglobulins: 6-month follow-up outcomes of the randomised controlled Swissped RECOVERY trial.
Andre MC; Sanchez C; Bressieux-Degueldre S; Perez MH; Wütz D; Blanchard-Rohner G; Grazioli S; Schöbi N; Trück J; Welzel T; Atkinson A; Schlapbach LJ; Bielicki J;
EClinicalMedicine; 2024 Jan; 67():102358. PubMed ID: 38107550
[TBL] [Abstract][Full Text] [Related]
5. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
7. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Respir Med; 2021 Dec; 9(12):1419-1426. PubMed ID: 34672950
[TBL] [Abstract][Full Text] [Related]
8. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
[TBL] [Abstract][Full Text] [Related]
9. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study.
Davies P; Evans C; Kanthimathinathan HK; Lillie J; Brierley J; Waters G; Johnson M; Griffiths B; du Pré P; Mohammad Z; Deep A; Playfor S; Singh D; Inwald D; Jardine M; Ross O; Shetty N; Worrall M; Sinha R; Koul A; Whittaker E; Vyas H; Scholefield BR; Ramnarayan P
Lancet Child Adolesc Health; 2020 Sep; 4(9):669-677. PubMed ID: 32653054
[TBL] [Abstract][Full Text] [Related]
10. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial.
Welzel T; Schöbi N; André MC; Bailey DGN; Blanchard-Rohner G; Buettcher M; Grazioli S; Koehler H; Perez MH; Trück J; Vanoni F; Zimmermann P; Atkinson A; Sanchez C; Whittaker E; Faust SN; Bielicki JA; Schlapbach LJ;
Front Pediatr; 2022; 10():905046. PubMed ID: 35669398
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):905-914. PubMed ID: 37865101
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
[TBL] [Abstract][Full Text] [Related]
16. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital.
Ramcharan T; Nolan O; Lai CY; Prabhu N; Krishnamurthy R; Richter AG; Jyothish D; Kanthimathinathan HK; Welch SB; Hackett S; Al-Abadi E; Scholefield BR; Chikermane A
Pediatr Cardiol; 2020 Oct; 41(7):1391-1401. PubMed ID: 32529358
[TBL] [Abstract][Full Text] [Related]
17. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
18. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Yu LM; Bafadhel M; Dorward J; Hayward G; Saville BR; Gbinigie O; Van Hecke O; Ogburn E; Evans PH; Thomas NPB; Patel MG; Richards D; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Shanyinde M; de Lusignan S; Andersson MI; Barnes PJ; Russell REK; Nicolau DV; Ramakrishnan S; Hobbs FDR; Butler CC;
Lancet; 2021 Sep; 398(10303):843-855. PubMed ID: 34388395
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 May; 397(10285):1637-1645. PubMed ID: 33933206
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2020 Oct; 396(10259):1345-1352. PubMed ID: 33031764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]